In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:Best practices in testing for NTRK fusions in solid tumorsOptimal use of approved TRK inhibitorsKey adverse events with TRK inhibitors and management strategiesEmerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agentsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental Therapeutics Director, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, Thoracic OncologyMemorial Sloan Kettering Cancer CenterNew York, New YorkPashtoon Kasi, MDAssistant ProfessorCollege of Medicine and OncologyHolden Comprehensive Cancer CenterUniversity of IowaIowa City, IowaContent based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.Link to full program: https://bit.ly/2PN0BWh

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related